Background: Recipients of ICD are likely to have several risk factors that could interfere with successful use of implantable cardioverter defibrillators (ICDs).
| INTRODUCTION
Implantable cardioverter defibrillators (ICDs) are often considered for prevention of sudden cardiac arrest in elderly patients and those at risk of survival due to both underlying heart conditions and comorbid conditions. The prognosis for ICD recipients with various risk factors remains an area of active investigation. There is conflicting evidence regarding the differential outcomes experienced with ICDs in women and men, but complication rates are higher in women. 1 Analysis of randomized controlled trials has suggested that outcomes may be worse in older patients and in patients with serious comorbidity. 2, 3 Other researchers have examined the relationship between the presence of nonischemic cardiomyopathy and the outcomes experienced following ICD. 2, [4] [5] [6] An exploration of these factors in a real-world population using claims data has not been published.
To expand the evidence base, this retrospective cohort study examined all-cause hospitalization and mortality, as well as devicerelated complications, including lead complications, at 1 year following ICD implantation in a large Medicare Advantage population. The objective was not to suggest appropriateness criteria for ICD procedures or to demonstrate the efficacy of ICDs, but rather to elucidate some of the factors that could influence general short-term success in order to help clinicians and patients set expectations. The following claims-based factors were evaluated as potential predictors of outcomes: age, sex, various cardiac conditions, and measures of general comorbidity.
| METHODS

| Data source and patient selection criteria
Adult patients who underwent outpatient ICD implantation between January 1, 2014 and September 30, 2015 were included in the analysis. Only outpatient ICD implantations were considered because the codes used to bill for inpatient ICD implantations do not allow differentiation between S-ICDs and TV-ICDs. Patients were excluded if they were not enrolled in a Medicare Advantage plan, their inclusion was not possible for plan contract reasons, or they were at especially high risk of mortality as evidenced by either enrollment in hospice or a diagnosis of end-stage renal disease (ESRD) in the year prior to implantation. Another reason for the hospice exclusion was that patients enrolled in both Medicare Advantage and hospice have portions of their medical care covered by Traditional Medicare; thus, the Medicare Advantage plan could have incomplete claims data related to outcomes in these patients. 7 
| Outcome measures and predictors
The following outcomes were measured at 12 months following implantation: mortality, nonlead device-related complications, lead complications, a composite measure of any complication (lead or nonlead), and a composite measure of any adverse outcome (mortality, lead complication, or nonlead complication). Lead complications were identified by CPT and ICD-9 or ICD-10 codes for insertion, removal, or repositioning of an electrode for a pacemaker or implantable defibrillator. Nonlead complications were identified by CPT and ICD-9 or ICD-10 codes for insertion, replacement, or removal of a defibrillator system or pulse generator, and by codes for relocation or revision of a cardiac device pocket. The 12-month follow-up period was chosen since it has been reported that while most dislodgements and system infections occur within 3 months after implantation, lead fractures continue to occur at later points in time. 8 Multiple factors were considered as potential independent determinants of outcomes: age (≥65 vs <65), sex, Charlson Comorbidity Index (CCI; Deyo method) score, 9 prior year hospitalization or emergency department (ED) visit, diagnosis of diabetes, diagnosis of heart failure, diagnosis of ischemic heart disease and indicators of a need for pacing. These indicators included variables for history of procedures related to pacing, diagnosis of bradycardia, and diagnosis of conduction disorder. The risk factors were identified using International Classification of Diseases, Ninth Edition (ICD-9) and/or Current Procedural Terminology (CPT) codes from medical claims and were based on the 12 months prior to ICD implantation. Administrative data were used to determine enrollment and mortality.
| Statistical analysis
Summary statistics for the patient characteristics were computed. The one-year cumulative survival probability for each outcome, with a 95% confidence interval, was calculated for the overall study population using the Kaplan-Meier method. To simultaneously adjust for all factors, a Cox Proportional Hazard model was constructed for each outcome measure. The variables included in the Cox models were tested for collinearity. Finally, adjusted survival curves were plotted based on regression coefficients and the average value or proportion of participants with each factor. 10 All analyses were performed using SAS Enterprise 9.4. Table 1 shows that patients were predominantly age 65 or older (80.9% over the age of 65; mean age of 70.9; SD of 8.9 years) and male (72.0%). A majority were hospitalized in the prior year (61.4%), and/or had a diagnosis of diabetes (53.5%). More than a third had a diagnosis of heart failure, bradycardia or conduction disorder, but only 13.0% overall had a history of procedures related to pacing in the previous 12 months. Stratified analysis of demographic and clinical characteristics showed that subgroups defined by key factors of interest were very similar in age, sex, and CCI score except where expected; for example, those with prior year hospitalization had a higher mean CCI score (Table S1, Supporting information).
| RESULTS
When one-year outcomes were determined using the Kaplan-Meier method (see Table 2 ), the unadjusted cumulative risk of 365-day post-procedure event-free survival was 89.6% for mortality, 91.5% for nonlead complications, 94.2% for lead complications, 89.1% for composite complications, and 80.1% for composite adverse outcomes. Table 3 pacing-related procedure were 20% to 55% less likely to survive the first year after implantation. However, male sex and age greater than 65 years were significantly associated with reduced complications. No association between ischemic heart disease and mortality or other outcomes was observed.
One-year, all-cause mortality in this study population, whose mean age was 71 years, was approximately 10%. This seems consistent with a reported weighted mortality of 15% over a mean of approximately 4 years in a meta-analysis of trials of ICD for primary prevention (weighted mean age, 61 years). 11 Likewise, another study reported 4-year mortality rates from 7% to 52%, depending on whether recipients of either primary or secondary ICD (mean age 62 years) had no comorbidities for indications unrelated to ICDs or had more than two such comorbidities. 12 The present study's findings In the present study, despite having fewer device-related complications, men were 24% less likely to survive the first year. In contrast, a regional database analysis did not find evidence supporting an association between sex and mortality. 13 The finding that general measures of morbidity were significantly associated with risk of mortality and the composite measure of any adverse outcome was likewise consistent with expectations and with previous research. 2, 3, 13 The association of heart failure (ischemic or nonischemic) with reduced mortality and the lack of an association of ischemic heart disease with outcomes require further exploration.
The adjusted survival curves for both lead and nonlead complications showed that the risk of device-related complications was greatest immediately after the procedure and then slowly decreased through the first year. The use of S-ICD in this population was very rare, which is in line with other reports of clinical practice: a recent analysis of 393 734 ICD implant procedures listed in the National Cardiovascular Data Registry ICD Registry between September 28, 2012
and March 31, 2015 found that only 0.9% of procedures were for S-ICD. 14 S-ICD provides a less invasive alternative to TV-ICD with comparable technical performance. 15, 16 It is seen as a safer alternative to TV-ICD, particularly in patients at high risk of infection and other complications, while providing similar health benefits. However, the true potential for this new technology to reduce adverse outcomes remains unknown.
| Limitations
As with any claims-based analysis, the study could not take into account a number of clinical factors because the necessary information is not available from claims. For example, it was not possible to adjust for clinical factors such as body mass index (BMI), concurrent cardiac resynchronization therapy, or number of leads implanted. It Age and sex distribution are also similar. Results may likewise not be generalizable to a different Medicare Advantage population.
| CONCLUSIONS
Results from this exploratory study suggest that most patients in a Medicare Advantage population survive without device-related complications for at least 12 months following outpatient ICD implantation.
The risk of 1-year mortality may be increased by male sex, age over 65, greater general morbidity, and heart failure. The study provided no evidence that ischemic heart disease increases the risk of mortality.
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